First-Line Treatment for Generalized Anxiety Disorder in Adults
For adults with GAD, start with either an SSRI (sertraline, escitalopram) or SNRI (venlafaxine extended-release) as first-line pharmacotherapy, combined with cognitive behavioral therapy when available, as both modalities demonstrate comparable efficacy with small to medium effect sizes. 1
Pharmacologic Treatment
First-Line Medications
SSRIs and SNRIs are the established first-line pharmacologic agents for GAD, supported by meta-analyses showing standardized mean differences of -0.55 compared to placebo 1. These medications demonstrate:
- Efficacy rates of 60-85% 2
- Small to medium effect sizes in controlled trials 1
- Favorable tolerability without considerable long-term adverse effects 3
Specific recommended agents include:
- Sertraline (SSRI)
- Escitalopram (SSRI)
- Venlafaxine extended-release (SNRI)
These medications should be prescribed as daily standing doses, not as-needed 3. The main pharmacologic decision is between selecting a daily maintenance medication versus short-acting agents for intermittent symptoms.
Critical Caveat: Benzodiazepines
Avoid benzodiazepines for GAD treatment due to risks of abuse, dependence, and cognitive impairment, particularly with long-term use 4, 3. If benzodiazepines are used, they should be strictly time-limited and only considered while awaiting the therapeutic effect of an SSRI/SNRI 3.
Second-Line Options
When first-line agents fail or are not tolerated, consider:
- Buspirone (azapirone)
- Pregabalin (anti-adrenergic)
- Second-generation antipsychotics (SGAs) 5
Psychotherapeutic Treatment
First-Line Psychotherapy
Cognitive behavioral therapy (CBT) is the psychotherapy with the strongest evidence base for GAD, demonstrating large effect sizes (Hedges g = 1.01) compared to psychological or pill placebo 1.
CBT can be delivered effectively in primary care settings through:
- Brief CBT protocols delivered by embedded behavioral health clinicians 3
- Individual face-to-face sessions (preferred format)
- Group therapy (alternative when individual therapy unavailable)
- Guided self-help when patients decline face-to-face CBT 6
The evidence shows that treatment gains are maintained at follow-up in 77.8% of studies with follow-up assessments 6.
Treatment Selection Algorithm
Step 1: Assess symptom severity
- Subthreshold symptoms (not meeting diagnostic criteria): Start with self-help and behavioral interventions 3
- Full diagnostic criteria for GAD: Proceed to Step 2
Step 2: Consider patient factors
- Patient preference for medication vs. therapy
- Treatment history and prior responses
- Medical/psychiatric comorbidities (particularly depression, which co-occurs in 72.7% of anxiety cases) 6
- Age considerations (geriatric patients may require dose adjustments)
- Reproductive planning in women of childbearing age
Step 3: Initiate treatment
- Monotherapy approach: Either SSRI/SNRI OR CBT based on patient preference and availability
- Combined approach: SSRI/SNRI + CBT when resources permit, though evidence for superiority of combination therapy over monotherapy is limited
Step 4: Implement Collaborative Care Management Use the Collaborative Care Model involving primary care clinicians, consulting psychiatrists, and care managers who monitor progress and provide behavioral treatment—this approach improves anxiety outcomes compared to usual primary care 3.
Monitoring and Follow-Up
Reassess monthly until symptoms subside, evaluating:
- Treatment adherence and compliance
- Adverse effects and patient satisfaction
- Symptom reduction using validated measures (GAD-7, HADS, BAI)
After 8 weeks without adequate response despite good compliance: Switch to alternative SSRI/SNRI, add CBT if on medication alone, or refer to specialty mental health care 4.
Consider medication tapering when symptoms are controlled and environmental stressors have resolved, though this requires careful monitoring given GAD's chronic nature 4, 7.
Common Pitfalls
- Underdetection: GAD presents with somatic symptoms (palpitations, shortness of breath, dizziness) that may be mistaken for medical conditions 1
- Inadequate dosing: When medications are prescribed, doses are often subtherapeutic 4
- Premature discontinuation: Patients with anxiety pathology commonly avoid follow-through on referrals due to avoidance behaviors inherent to the disorder 4
- Overreliance on benzodiazepines: These carry significant long-term risks and should not be first-line 3